Concentrations of two markers of bone turnover were measured in 160 subjects from fasting serum samples collected prior to the injection on time 1, at four weeks after the baseline injection, and before shots at 6, 12, 24, and 36 months. Bone-turnover marker serum C-telopeptide of type I collagen was evaluated with the use of enzyme-connected immunosorbent assay , and intact serum procollagen type I N-terminal propeptide was evaluated with the use of radioimmunoassay . Adverse Events Physicians at research sites reported adverse occasions that were coded seeing that preferred terms in the Medical Dictionary for Regulatory Activities system. All deaths and serious adverse events that were probably related to coronary disease were adjudicated by way of a committee of cardiologists using predefined requirements.Results Study Participants A total of 6543 couples who were discordant for HIV-1 serologic position were screened for the study; 3408 of these couples were enrolled. The companions who acquired HIV-1 infection were designated to receive acyclovir randomly, at a dose of 400 mg daily twice, or placebo . After 24 couples in each combined group were excluded based on confirmatory tests for HIV-1 and HSV-2, the final analysis included 3360 lovers . Both groups had similar baseline characteristics .